Thrombocytopenia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="5" |Category
! colspan="2" rowspan="5" |Condition
! colspan="2" rowspan="5" |Condition
! rowspan="5" |Mechanism
! rowspan="5" |Mechanism
Line 32: Line 31:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
Line 49: Line 47:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!Decreased platelet production
!Platelet destruction in bloodstream
!Platelet destruction in bloodstream
!Platelet destruction in spleen/liver
!Platelet destruction in spleen/liver
Line 56: Line 53:
!WBC
!WBC
|-
|-
! rowspan="15" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematology
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
! align="center" style="background:#DCDCDC;" + |Myelodysplastic syndromes
! align="center" style="background:#DCDCDC;" + |Myelodysplastic syndromes
Line 513: Line 509:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!Category
! colspan="2" |Condition
! colspan="2" |Condition
!Mechanism
!Mechanism
Line 544: Line 539:
!Associated findings
!Associated findings
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction
Line 665: Line 659:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection-induced
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
! align="center" style="background:#DCDCDC;" + |Sepsis
! align="center" style="background:#DCDCDC;" + |Sepsis
Line 778: Line 771:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Confirm the diagnosis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 784: Line 781:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Bone marrow examination and culture
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Immune mediated
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 819: Line 812:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Might resolve spontaneously
|-
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
Line 883: Line 876:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!Category
! colspan="2" |Condition
! colspan="2" |Condition
!Mechanism
!Mechanism
Line 914: Line 906:
!Associated findings
!Associated findings
|-
|-
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medication/toxicity
! align="center" style="background:#DCDCDC;" + |Antibiotics/
! align="center" style="background:#DCDCDC;" + |Drug-induced immune thrombocytopenia
Antiepileptics
! align="left" style="background:#DCDCDC;" + |
! align="left" style="background:#DCDCDC;" + |
* Antibiotics
** Sulfonamides
** Ampicillin
** Piperacillin
** Vancomycin
** Rifampin
* Older antiepileptic agents
** carbamazepine
** Phenytoin
* Quinine
* Quinine
* Sulfonamides
* Carbamazepine
* Phenytoin
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 953: Line 939:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Resolution after discontinue
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
Line 965: Line 951:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Not
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 981: Line 970:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Increased risk of thrombosis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
Line 1,077: Line 1,063:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,139: Line 1,124:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
!Category
! colspan="2" |Condition
! colspan="2" |Condition
!Mechanism
!Mechanism
Line 1,170: Line 1,154:
!Associated findings
!Associated findings
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
| align="center" style="background:#F5F5F5;" + |Platelet destruction  
| align="center" style="background:#F5F5F5;" + |Platelet destruction  
Line 1,261: Line 1,244:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |

Revision as of 15:33, 15 August 2018

Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombocytopenia from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombocytopenia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombocytopenia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombocytopenia differential diagnosis

CDC on Thrombocytopenia differential diagnosis

Thrombocytopenia differential diagnosis in the news

Blogs on Thrombocytopenia differential diagnosis

Directions to Hospitals Treating Thrombocytopenia

Risk calculators and risk factors for Thrombocytopenia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farbod Zahedi Tajrishi, M.D.

Overview

Thrombocytopenia has a broad range of potential causes. While a good history and physical examination can be helpful to diagnose some of these causes such as drug-induced thrombocytopenia, they usually don't suffice and further evaluation is often needed. There are also some useful points that may guide the physician to an appropriate diagnosis. For example, asymptomatic, isolated thrombocytopenia most probably suggests ITP, while thrombocytopenia in critically ill, hospitalized patients is usually suggestive of iatrogenic causes (eg. dilution), platelet consumption, bone marrow suppression from infection/sepsis, or even drug-induced thrombocytopenia. One should consider however, that a wide variety of other conditions such as autoimmune disorders, nutrient deficiencies, thrombotic microangiopathies could all as well cause thrombocytopenia.

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Condition Mechanism Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Age range History Symptoms Signs
Lab Findings Imaging
Fever Rash Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT BT UA
Platelet destruction in bloodstream Platelet destruction in spleen/liver Plt HB WBC
Bone marrow disorders Myelodysplastic syndromes +
Aplastic anemia +
Acute leukemia +
Paroxysmal nocturnal hemoglobinuria (PNH) +
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP) +
Hemolytic uremic syndrome (HUS) +
DIC +
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Nutrient deficiencies Folate, vitamin B12, copper +
Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Immune thrombocytopenia Antibody-mediated platelet destruction +
Systemic lupus erythematosus (SLE) +
Antiphospholipid syndrome (APS) Autoantibody-mediated syndrome +
Felty's syndrome Splenomegaly +
Bacterial infections Sepsis Direct bone marrow suppression + +
Helicobacter pylori Immune thrombocytopenia +
Tick-borne infection +
Viral infections HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
+ + + ↓↓ Confirm the diagnosis Bone marrow examination and culture
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus Immune mediated + Might resolve spontaneously
Intracellular parasites Malaria
Babesiosis
Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Antibiotics/

Antiepileptics

  • Quinine
  • Sulfonamides
  • Carbamazepine
  • Phenytoin
Occurrence of drug-dependent, platelet-reactive antibodies + + Resolution after discontinue
Heparin-induced thrombocytopenia + Not - Increased risk of thrombosis
Cytotoxic chemotherapy +
Radiation therapy Predictable, dose-dependent myelosuppression +
OTC agents Quinine-containing beverages
Chronic liver disease +
Portal hypertension
Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Giant capillary hemangioma Platelet destruction +
Aortic aneurysm Platelet destruction +
Cardiopulmonary bypass Platelet destruction +
Alcohol +
Post-transfusion purpura Immune mediated platelet destruction +
Gestational thrombocytopenia
HELLP syndrome

References